Bristol Myers Squibb Co. reported an insider ownership update for Phyllis R. Yale, a non-employee director, covering activity dated June 30, 2026. The filing, made July 2, 2026, concerns Yale’s holdings of Deferred Share Units, a derivative security tied to Bristol Myers Squibb common stock. The reported security is a Deferred Share Unit, or DSU. According to the explanatory notes, each DSU will convert into one share of Bristol Myers Squibb common stock upon settlement. The units become settleable when Yale ceases to serve as a director or at a future date she previously specified. The filing also states that the reported holdings include deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors. The document indicates an ownership-change report in Yale’s derivative securities as of June 30, specifically in the number of derivative securities beneficially owned following the reported transaction or transactions. However, the provided filing text does not include the transaction table details needed to identify the exact number of DSUs acquired, disposed of, or held afterward. It also does not show a transaction code, transaction price, or precise post-transaction ownership amount. Because DSUs are deferred compensation instruments rather than open-market stock purchases, the filing is most relevant as a governance and compensation disclosure. It shows that Yale’s director compensation and reinvested dividends continue to be tracked in Bristol Myers Squibb stock-linked units, aligning part of her compensation with the company’s share performance. The filing was signed on Yale’s behalf by Amy Fallone as attorney-in-fact on July 2, 2026.